Literature DB >> 29261840

Herpes Zoster Rates in a Large Cohort of Patients With Systemically Treated Psoriasis.

Katherine A Levandoski1,2, Charles P Quesenberry3, Ai-Lin Tsai3, Maryam M Asgari1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29261840      PMCID： PMC5839271          DOI： 10.1001/jamadermatol.2017.4840

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  6 in total

Review 1.  The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.

Authors:  L Adelzadeh; N Jourabchi; J J Wu
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-11-04       Impact factor: 6.166

2.  The risk of herpes zoster in patients with psoriasis: A retrospective records-based observational study.

Authors:  Matteo Megna; Maddalena Napolitano; Fabio Ayala; Nicola Balato
Journal:  Indian J Dermatol Venereol Leprol       Date:  2016 Nov-Dec       Impact factor: 2.545

3.  Serious infections among a large cohort of subjects with systemically treated psoriasis.

Authors:  Allison S Dobry; Charles P Quesenberry; G Thomas Ray; Jamie L Geier; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2017-09-13       Impact factor: 11.527

4.  Risk of Herpes zoster in patients with psoriasis treated with biologic drugs.

Authors:  J Dreiher; F S Kresch; D Comaneshter; A D Cohen
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-09-16       Impact factor: 6.166

5.  Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.

Authors:  Maryam M Asgari; G Thomas Ray; Jamie L Geier; Charles P Quesenberry
Journal:  J Am Acad Dermatol       Date:  2017-02-03       Impact factor: 11.527

6.  Systemic Therapy for Psoriasis and the Risk of Herpes Zoster: A 500,000 Person-year Study.

Authors:  Guy Shalom; Devy Zisman; Haim Bitterman; Ilana Harman-Boehm; Sari Greenberg-Dotan; Jacob Dreiher; Ilan Feldhamer; Hadas Moser; Ariel Hammerman; Yoram Cohen; Arnon D Cohen
Journal:  JAMA Dermatol       Date:  2015-05       Impact factor: 10.282
  6 in total
  3 in total

1.  Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

Authors:  K B Gordon; M Lebwohl; K A Papp; H Bachelez; J J Wu; R G Langley; A Blauvelt; B Kaplan; M Shah; Y Zhao; R Sinvhal; K Reich
Journal:  Br J Dermatol       Date:  2021-11-24       Impact factor: 11.113

2.  Comparative risk of herpes zoster in patients with psoriatic disease on systemic treatments: a systematic review and network meta-analysis.

Authors:  Hsien-Yi Chiu; Yi-Teng Hung; Shi-Wei Huang; Yu-Huei Huang
Journal:  Ther Adv Chronic Dis       Date:  2022-05-02       Impact factor: 4.970

3.  Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: A systematic review and meta-analysis.

Authors:  Ailing Zou; Yongjun Chen; Nian Shi; Yu Ye
Journal:  Medicine (Baltimore)       Date:  2021-10-08       Impact factor: 1.889
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.